Products

As of June 2020

Brand Name Launch Indications Licensor
1 Nobelzin® Apr 2008 Wilson’s disease Teva
2 Lunabell® LD Jul 2008 dysmenorrhea Janssen
3 Nobelbar® Dec 2008 neonatal seizures,
status epilepticus
in-house/
Kagawa Univ
4 Fostoin® Jan 2012 status epilepticus,
prevention of postoperative seizures, etc.
Pfizer
5 Gliadel® Jan 2013 malignant glioma Eisai
6 Indacin® Jan 2013 patent ductus arteriosus of prematurity Lundbeck
7 Cosmegen® Jan 2013 Wilms’ tumor,
chorionepitelioma,
pediatric solid malignant tumor, etc.
Lundbeck
8 Lunabell® ULD Sep 2013 dysmenorrhea Janssen
9 Alabel® Sep 2013 diagnosis of malignant glioma medac
10 Unitalc® Dec 2013 prevention of recurrent malignant pleural effusion Novatech/
Nagoya Medical Center
11 Respia® Dec 2014 apnea of prematurity Nippon Boehringer
(co-development)
12 Rapalimus® Dec 2014 lymphangioleiomyomatosis Pfizer/
Niigata Univ
13 Zanosar® Feb 2015 gastroenteropancreatic neuroendocrine tumor Keocyt
14 Nobelzin® Mar 2017 hypozincemia In-house
15 Rapalimus® Gel Jun 2018 tuberous sclerosis-associated skin lesions Osaka Univ/
In-house
16 TITANBRIDGE®
(medical device)
Jul 2018 adductor spasmodic dysphonia TRI
(Translational Research Center
for Medical Innovation)/
Kumamoto Univ
17 Jemina® Oct 2018 dysmenorrhea In-house
18 Retympa®250μg Set Dec 2019 tympanic perforation TRI/
Kaken
19 Melatobel®250μg Set Jun 2020 Sleep-onset difficulty associated with neurodevelopmental disease in children in-house
Research and Development

R&D of Nobelpharma

Pipeline

Products

PAGE TOP
  1. HOME
  2. Research and Development
  3. Products